FDA Grants Accelerated Approval to J&J’s RYBREVANT FASPRO
The FDA approved the subcutaneous therapy for advanced head and neck cancer, according to Johnson & Johnson.
NEW BRUNSWICK, N.J., Nov. 5, 2026 // -- Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single age…